BMO Capital downgraded Tokai Pharmaceuticals (NASDAQ: TKAI) from Outperform to ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Downgrades

BMO Capital Downgrades Tokai Pharmaceuticals (TKAI) to Market PerformJuly 26, 2016 10:43 AM Stifel Downgrades Tokai Pharmaceuticals (TKAI) to HoldJuly 26, 2016 9:45 AM Wells Fargo Downgrades Tokai Pharmaceuticals (TKAI) to Market PerformJuly 26, 2016 8:23 AM Tokai Pharma (TKAI) to Cease ARMOR3-SV Clinical TrialJuly 26, 2016 7:05 AM Tokai Pharmaceuticals Announces Clinical UpdateJuly 26, 2016 7:00 AM Tokai Pharma (TKAI) trading halted with news pendingJuly 26, 2016 6:55 AM